MAP kinase phosphatase-1 is induced in abnormal fibers in inclusion body myositis

Neurology

Volumn 61, Issue 3, 2003, Pages 322-326

  Nakano, Satoshi ^a   Shinde, A ^a,b   Ito, H ^a   Kusaka, H ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 2; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 3; PHOSPHATASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCLUSION BODY MYOSITIS; MUSCLE BIOPSY; MUSCLE CELL; MYOTUBE; PATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION;

EID: 0043126949     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000076479.29079.10     Document Type: Article

References (26)

1. Griggs R, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-713.
2. Mikol J, Engel AG. Inclusion body myositis. In: Engel AG, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill, 1994;1384-1398.
3. Karpati G, Hohlfeld R. Biologically stressed muscle fibers in sporadic IBM: a clue for the enigmatic etiology? Neurology 2000;54:1020-1021.
4. Nakano S, Kawashima S, Satoi H, et al. Active form of ERK2 is a major phosphorylated protein in vacuolated fibers in sporadic inclusion body myositis. Muscle Nerve 1998;S130. Abstract.
5. Wilczynski G, Engel WK, Askanas V. Association of active extracellular signal-regulated protein kinase with paired helical filaments of inclusion-body myositis muscle suggests its role in inclusion-body myositis tau phosphorylation. Am J Pathol 2000;156:1835-1840.
6. Li M, Dalakas M. The muscle mitogen-activated protein kinase is altered in sporadic inclusion body myositis. Neurology 2000;54:1665-1669.
7. Nakano S, Shinde A, Kawashima S, Nakamura S, Akiguchi I, Kimura J. Inclusion body myositis: expression of extracellular signal-regulated kinase and its substrate. Neurology 2001;56:87-93.
8. Robinson M, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186.
9. Keyse S. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000;12:186-192.
10. Nonaka I, Murakami N, Suzuki Y, Kawai M. Distal myopathy with rimmed vacuoles. Neuromuscul Disord 1998;8:333-337.
11. Cha H, Shapiro P. Tyrosine-phosphorylated extracellular signal-regulated kinase associates with the Golgi complex during G2/M phase of the cell cycle. J Cell Biol 2001;153:1355-1367.
12. Finch A, Davis W, Carter WG, Saklatvala J. Analysis of mitogen-activated protein kinase pathways used by interleukin 1 in tissues in vivo: activation of hepatic c-Jun N-terminal kinases 1 and 2, and mitogen-activated protein kinase kinases 4 and 7. Biochem J 2001;353:275-281.
13. Reffas S, Schlegel W. Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells. Biochem J 2000;352:701-708.
14. Banker B, Engel AG. Basic reactions of muscle. In: Engel AG, Franzini-Armstrong C, eds. Myology. 2nd ed. New York: McGraw-Hill, 1994;832-888.
15. Kyriakis J, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869.
16. Bennett A, Tonks NK. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 1997;278:1288-1291.
17. Schillace R, Scott JD. Organization of kinases, phosphatases, and receptor signaling complexes. J Clin Invest 2000;103:767-772.
18. Grounds M. Muscle regeneration: molecular aspects and therapeutic implications. Curr Opin Neurol 1999;12:353-543.
19. Lundberg I, Ulfgren A, Nyberg P, Andersson U, Klarreskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865-874.
20. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999;18:664-674.
21. Banwell B, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000;54:1033-1041.
22. Dalakas M, Illa I, Gallardo E, Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol 1997;41:100-104.
23. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-123.
24. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29:83-87.
25. Karpati G, Holland P. Sweetening the pot in muscle. Genetic defects of protein glycosylation causing muscle disease. Neurology 2002;59:1674-1676.
26. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001;291:2376-2378.